Immatics' cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help?

Immatics has delivered evidence that its TCR-engineered cell therapies can move the needle in solid tumors, revealing 50% of heavily pretreated patients responded to its candidate despite taking less than the target dose. The challenge now? To improve the durability of the responses.